Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie H Hayes

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Continuum (Minneapolis, Minn.)|October 18, 2023
Hereditary NeuropathiesLeslie H Hayes, Reza Sadjadi
Seminars in Pediatric Neurology|April 27, 2024
Neuromuscular problems of the critically Ill neonate and childLeslie H Hayes, Basil T Darras
BMC Pediatrics|February 8, 2020
Hypoglycemia in patients with congenital muscle diseaseLeslie H Hayes, Pomi Yun, Payam Mohassel, et al.
Neurology. Genetics|July 15, 2025
Retrospective Cohort Analysis of Clinical, Molecular, and Histopathologic Characteristics of 275 Patients With Nemaline MyopathyClara Hildebrandt, Casie A Genetti, Tanya Logvinenko, et al.
Neuromuscular Disorders : NMD|April 19, 2017
Cytoplasmic body pathology in severe ACTA1-related myopathy in the absence of typical nemaline rodsSandra Donkervoort, Sophelia H S Chan, Leslie H Hayes, et al.
Nature Medicine|December 8, 2025
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
The New England Journal of Medicine|September 23, 2016
The Role of PIEZO2 in Human MechanosensationAlexander T Chesler, Marcin Szczot, Diana Bharucha-Goebel, et al.
Nature Medicine|January 28, 2026
Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
Muscle & Nerve|June 16, 2026
Electrodiagnostic Studies as a Diagnostic and Prognostic Tool in Acute Flaccid MyelitisJelte Helfferich, Judith M Vonk, Melodie Aubart, et al.
Neurology. Genetics|June 25, 2024
Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related DystrophyA Reghan Foley, Pomi Yun, Meganne E Leach, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Continuum (Minneapolis, Minn.)|October 18, 2023
Hereditary NeuropathiesLeslie H Hayes, Reza Sadjadi
Seminars in Pediatric Neurology|April 27, 2024
Neuromuscular problems of the critically Ill neonate and childLeslie H Hayes, Basil T Darras
BMC Pediatrics|February 8, 2020
Hypoglycemia in patients with congenital muscle diseaseLeslie H Hayes, Pomi Yun, Payam Mohassel, et al.
Neurology. Genetics|July 15, 2025
Retrospective Cohort Analysis of Clinical, Molecular, and Histopathologic Characteristics of 275 Patients With Nemaline MyopathyClara Hildebrandt, Casie A Genetti, Tanya Logvinenko, et al.
Neuromuscular Disorders : NMD|April 19, 2017
Cytoplasmic body pathology in severe ACTA1-related myopathy in the absence of typical nemaline rodsSandra Donkervoort, Sophelia H S Chan, Leslie H Hayes, et al.
Nature Medicine|December 8, 2025
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
The New England Journal of Medicine|September 23, 2016
The Role of PIEZO2 in Human MechanosensationAlexander T Chesler, Marcin Szczot, Diana Bharucha-Goebel, et al.
Nature Medicine|January 28, 2026
Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
Muscle & Nerve|June 16, 2026
Electrodiagnostic Studies as a Diagnostic and Prognostic Tool in Acute Flaccid MyelitisJelte Helfferich, Judith M Vonk, Melodie Aubart, et al.
Neurology. Genetics|June 25, 2024
Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related DystrophyA Reghan Foley, Pomi Yun, Meganne E Leach, et al.
Pageof 2